Onkologie, Hämatologie - Daten und Informationen
SitemapSitemap  


Literatur zu Kapitel 1: Einführung, Epidemiologie, Symptomatik

Autor/en: Dietrich Peest
Letzte Änderung: 30.06.2011
  • Alexander DD et al.
    Multiple myeloma: a review of the epidemiologic literature.
    Int J Cancer (2007), 120 Suppl 12, 40-61


  • Alexanian R et al.
    Treatment for multiple myeloma.
    JAMA (1969), 208, 1680-1685


  • Auwerda JJ et al.
    Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma.
    Haematologica 2007;92:279-280. PMID:17296591
    [Medline]


  • Axelsson U, Bachmann R, Hällén J.
    Frequency of pathological proteins (M-components) in 6995 sera from an adult population.
    Acta Med Scand 1966;179:235-47. PMID:4160039
    [Medline]


  • Bataille R et al.
    Osteoblast stimulation in multiple myeloma lacking lytic bone lesions.
    Br J Haematol 1990;76:484-487. PMID:2265110
    [Medline]


  • Bergsagel DE et al.
    Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806).
    Cancer Chemother Rep 1962;21:87-99. PMID:13867794
    [Medline]


  • Blokhin N et al.
    Clinical experiences with sarcolysin in neoplastic diseases.
    Ann N Y Acad Sci 1958;68:1128-1132. PMID:13627766
    [Medline]


  • Brouet JC et al.
    Biologic and clinical significance of cryoglobulins. A report of 86 cases.
    Am J Med 1974;57:775-788. PMID:4216269
    [Medline]


  • Buxbaum J
    Mechanisms of disease: monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease.
    Hematol Oncol Clin North Am 1992;6:323-346. PMID:1582976
    [Medline]


  • Buxbaum J, Gallo G.
    Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases.
    Hematol Oncol Clin North Am 1999;13:1235-1248. PMID:10626147
    [Medline]


  • Chapel HM et al.
    Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma.
    Lancet 1994;343:1059-1063. PMID:7909099
    [Medline]


  • Colwell NS, Tollefsen DM, Blinder MA.
    Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder. Br J Haematol 1997;97:219-226. PMID:9136969
    [Medline]


  • Crawford J, Cox EB, Cohen HJ.
    Evaluation of hyperviscosity in monoclonal gammopathies.
    Am J Med 1985;79:13-22. PMID:4014299
    [Medline]


  • Cuzick J et al.
    A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council’s working party on leukaemia in adults.
    Br J Cancer 1987;55:523-529. PMID:3300761
    [Medline]


  • Delauche MC, Clauvel JP, Seligmann M.
    Peripheral neuropathy and plasma cell neoplasias: a report of 10 cases.
    Br J Haematol 1981;48:383-392. PMID:6266447
    [Medline]


  • Dimopoulos MA et al.
    Risk of disease progression in asymptomatic multiple myeloma.
    Am J Med 1993;94:57-61. PMID:8420300
    [Medline]


  • Dispenzieri A, Kyle RA.
    Neurological aspects of multiple myeloma and related disorders.
    Best Pract Res Clin Haematol 2005;18:673-688.PMID:16026744
    [Medline]


  • Durie BGM, Salmon SE.
    A clinical staging system for multiple myeloma.
    Cancer 1975;36:842-854. PMID:1182674
    [Medline]


  • Durie BG et al.
    Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.
    Hematol J 2003;4:379-398. PMID:14671610
    [Medline]


  • Epidemiologisches Krebsregister Niedersachsen, Krebsregister (2003). http://www.krebsregister-niedersachsen.de


  • Facon T et al.
    Prognostic factors in low tumour mass asymptomatic multiple myeloma: a report on 91 patients. The Groupe d’Etudes et de Recherche sur le Myelome (GERM) 8590.
    Am J Hematol 1995;48:71-75. PMID:7847344
    [Medline]


  • Fahey JL, Barth WF, Solomon A.
    Serum hyperviscosity syndrome.
    JAMA 1965;192:464-467. PMID:14284847
    [Medline]


  • Fahey JL et al.
    Infection, antibody response and gamma globulin components in multiple myeloma and macroglobulinemia.
    Am J Med 1963;35:698-707. PMID:14076022
    [Medline]


  • Fassas AB et al.
    Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations.
    Br J Haematol 2002;117:103-108. PMID:11918539
    [Medline]


  • Fefer A et al.
    Treatment of multiple myeloma (MM) with chemoradiotherapy and identical twin bone marrow transplantation.
    Proc Am Soc Clin Oncol 1982;1:C-731.


  • Giuliani N, Rizzoli V, Roodman GD.
    Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.
    Blood 2006;108:3992-3996. PMID:16917004
    [Medline]


  • Gonzalez F, Trujillo JM, Alexanian R.
    Acute leukemia in multiple myeloma.
    Ann Intern Med 1977;86:440-443. PMID:403840
    [Medline]


  • Hafner O et al.
    Nekrobiotisches Xanthogranulom bei IgG-kappa-Plasmozytom und Quincke-Odem.
    Hautarzt 1994;45:339-343. PMID:8050906
    [Medline]


  • Hargreaves RM et al.
    Immunological factors and risk of infection in plateau phase myeloma.
    J Clin Pathol 1995;48:260-266. PMID:7730490
    [Medline]


  • Haubitz M, Peest D, Myeloma - new approaches to combined nephrological-haematological management.
    Nephrol Dial Transplant 2006;21:582-590. PMID: 16396976
    [Medline]


  • Hjorth M et al.
    Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - a randomized study. Myeloma Group of Western Sweden.
    Eur J Haematol 1993;50:95-102. PMID:8440364
    [Medline]


  • International Myeloma Working Group, Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.
    Br J Haematol 2003;121:749-757. PMID:12780789
    [Medline]


  • Jacobson DR, Zolla-Pazner S.
    Immunosuppression and infection in Multiple Myeloma.
    Semin Oncol 1986;13:282-290. PMID:3532328
    [Medline]


  • Kariyawasan CC et al.
    Multiple myeloma: causes and consequences of delay in diagnosis.
    QJM 2007;100:635-640. PMID:17846059
    [Medline]


  • Kelly JJ et al.
    The spectrum of peripheral neuropathy in myeloma.
    Neurology 1981;31:24-31. PMID:6256682
    [Medline]


  • Klingemann HG, Egbring R, Havemann K.
    Incomplete fibrin formation and highly elevated Factor XIII activity in multiple myeloma.
    Scand J Haematol 1981;27:253-262. PMID:6810448
    [Medline]


  • Kosmo MA, Gale RP.
    Plasma cell leukemia.
    Semin Hematol 1987;24:202-208. PMID: 3116673
    [Medline]


  • Kyle RA.
    Multiple myeloma: an odyssey of discovery.
    Br J Haematol 2000;111:1035-1044. PMID:11167737
    [Medline]


  • Kyle RA.
    Henry Bence Jones - physician, chemist, scientist and biographer: a man for all seasons.
    Br J Haematol 2001;115:13-18. PMID: 11722404
    [Medline]


  • Kyle RA, Rajkumar SV.
    Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.
    Br J Haematol 2007;139:730-743. PMID:18021088
    [Medline]


  • Kyle RA et al.
    Review of 1027 patients with newly diagnosed multiple myeloma.
    Mayo Clin Proc 2003;78:21-33. PMID:12528874
    [Medline]


  • Kyle RA et al.
    Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades.
    Cancer 2004;101:2667-2674. PMID:15481060
    [Medline]


  • Kyle RA et al.
    Prevalence of monoclonal gammopathy of undetermined significance.
    N Engl J Med 2006;354:1362-1369. PMID: 16571879
    [Medline]


  • Lecouvet FE et al.
    Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey.
    Br J Haematol 1999;106:35-39. PMID:10444160
    [Medline]


  • Longsworth LG, Shedlovsky T, MacInnes DA.
    Electrophoretic patterns of normal and pathological human blood serum and plasma.
    J Exp Med 1939;70:399-413. PMID:19870918
    [Medline]


  • Ludwig H.
    Die Klinik des multiplen Myeloms.
    Onkologie 1986;9:202-208. PMID:3531947
    [Medline]


  • Ludwig H, Kumpan W, Sinzinger H.
    Radiography and bone scintigraphy in multiple myeloma: a comparative analysis.
    Brit J Radiol 1982;55:173-181. PMID:7066617
    [Medline]


  • McBride W, Jackman J-DJ, Grayburn PA.
    Prevalence and clinical characteristics of a high cardiac output state in patients with multiple myeloma.
    Am J Med 1990;89:21-24. PMID:2368788
    [Medline]


  • McElwain TJ, Powles RL.
    High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.
    Lancet 1983;2:822-824. PMID:6137651
    [Medline]


  • McGrath MA, Penny R.
    Paraproteinemia: blood hyperviscosity and clinical manifestations.
    J Clin Invest 1976;58:1155-1162. PMID:993338
    [Medline]


  • Mellstedt H et al.
    Interferon therapy in myelomatosis.
    Lancet 1979;1:245-247. PMID:84901
    [Medline]


  • Oshima K et al.
    Clinical and pathologic findings in 52 consecutively autopsied cases with multiple myeloma.
    Am J Hematol 2001;67:1-5. PMID:11279649
    [Medline]


  • Myeloma Trialists’ Collaborative Group.
    Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials.
    J Clin Oncol 1998;16:3832-3842. PMID:9850028
    [Medline]


  • Palumbo A et al.
    Correlation between fatigue and hemoglobin level in multiple myeloma patients: results of a cross-sectional study.
    Haematologica 2005;90:858-860. PMID:15951304
    [Medline]


  • Patriarca F et al.
    Multiple myeloma: presenting features and survival according to hospital referral. Eastern Cooperative Study Group on Monoclonal Gammopathies.
    Leuk Lymphoma 1998;30:551-562. PMID:9711917
    [Medline]


  • Peest D, Coldewey R, Deicher H.
    Overall vs. tumour-related survival in multiple myeloma.
    Eur J Cancer 1991;27:672-672. PMID:1828984
    [Medline]


  • Peest D et al.
    Prognostic value of clinical, laboratory, and histological characteristics in multiple myeloma: improved definition of risk groups.
    Eur J Cancer 1993;29A:978-983. PMID:8499152
    [Medline]


  • Peest D et al.
    A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group.
    Eur J Cancer 1995;31A:146-151. PMID:7718318
    [Medline]


  • Petersen SL, Wagner A, Gimsing P.
    Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature.
    Am J Hematol 1999;62:228-233. PMID:10589078
    [Medline]


  • Preston FE et al.
    Myelomatosis and the hyperviscosity syndrome.
    Br J Haematol 1978;38:517-530. PMID:646950
    [Medline]


  • Requena L et al.
    Generalized livedo reticularis associated with monoclonal cryoglobulinemia and multiple myeloma.
    J Cutan Pathol 2007;34:198-202. PMID:17244034
    [Medline]


  • Resnick D et al.
    Plasma-cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes: the POEMS syndrome.
    Radiology 1981;140:17-22. PMID:7244223
    [Medline]


  • Riccardi A et al.
    Changing clinical presentation of multiple myeloma.
    Eur J Cancer 1991;27:1401-1405. PMID:1835856
    [Medline]


  • Robertson JD et al.
    Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma.
    Br J Cancer 2000;82:1261-1265. PMID:10755398
    [Medline]


  • Roodman GD.
    Pathogenesis of myeloma bone disease.
    Blood Cells Mol Dis 2004;32:290-292. PMID:15003820
    [Medline]


  • Salmon SE, Wampler SE.
    Multiple myeloma: quantitative staging and assessment of response with a programmable pocket calculator.
    Blood 1977;49:379-389. PMID: 836948
    [Medline]


  • Sasaki K et al.
    Analysis of serum angiogenic factors in a young multiple myeloma patient with high-output cardiac failure.
    Int J Hematol 2007;86:72-76. PMID:17675271
    [Medline]


  • Singhal S et al.
    Antitumor activity of thalidomide in refractory multiple myeloma.
    N Engl J Med 1999;341:1565-1571. PMID:10564685
    [Medline]


  • Solomon A, Weiss DT, Kattine AA.
    Nephrotoxic potential of Bence Jones proteins.
    N Engl J Med 1991;324:1845-1851. PMID:1904132
    [Medline]


  • Tiselius A, Kabat EA.
    An electrophoretic study of immune sera and purified antibody preparations.
    J Exp Med 1939;69:119-131. PMID:19870831
    [Medline]


  • Tong Y et al.
    The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients.
    Am J Hematol 2007;82:403-404. PMID:17133426
    [Medline]


  • Twomey JJ, Houston MB.
    Infections complicating multiple myeloma and chronic lymphocytic leukemia.
    Arch Intern Med 1973;132:562-565. PMID:4542660
    [Medline]


  • Valentine EA et al.
    Necrobiotic xanthogranuloma with IgA multiple myeloma: a case report and literature review.
    Am J Hematol 1990;35:283-285. PMID:2239926
    [Medline]


  • Weber DM et al.
    Prognostic features of asymptomatic multiple myeloma.
    Br J Haematol 1997;97:810-814. PMID:9217181
    [Medline]


  • Wisloff F et al.
    Incidence and follow-up of asymptomatic multiple myeloma. The myeloma project of health region I in Norway.
    Eur J Haematol 1991;47:338-341. PMID:1761119
    [Medline]


  • Zangari M, et al.
    Hemostatic dysfunction in paraproteinemias and amyloidosis.
    Semin Thromb Hemost 2007;33:339-349. PMID:17525891
    [Medline]


Bei ONKODIN publiziert in Kooperation mit "Deutscher Ärzte-Verlag"; Publikation als Buch: Deutscher Ärzte-Verlag  Deutscher Ärzte-Verlag [Mehr]
Aktuelle Berichte vom 58th
ASH Annual Meeting 2016,
San Diego, Kalifornien, USA [Mehr]
2016 ASCO Annual Meeting - aktuelle Berichte. Dieser Service wird gefördert durch:
mehr 
[Mehr]